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Objectives: Schizophrenia (SZ) is a complex psychiatric disorder that has a strong
genetic basis. Dystrobrevin-binding protein 1 (DTNBP1) is one of the genes thought to be
pivotal in regulating the glutamatergic system. Studies have suggested that variations in
DTNBP1 confer susceptibility to SZ and clinical symptoms. Here, we performed a two-
stage independent verification study to identify polymorphisms of the DTNBP1 gene that
might be associated with SZ in the Han Chinese population.
Methods: In stage 1, 14 single nucleotide polymorphisms (SNPs) were genotyped in 528
paranoid SZ patients and 528 healthy controls (HCs) using the Illumina GoldenGate
assays on a BeadStation 500G Genotyping System. In stage 2, ten SNPs were
genotyped in an independent sample of 1,031 SZ patients and 621 HCs using the
Illumina 660k Genotyping System. Clinical symptoms were assessed using the Positive
and Negative Syndrome Scale.
Results: There was a significant association related to allele frequency, and a trend
association in relation to genotype between SZ patients and HCs at rs4712253 (p = 0.03
and 0.05, respectively). These associations were not evident following Bonferroni
correction (p > 0.05 for both). Haplotype association analysis revealed that only two
haplotypes (GAG and GAA; rs16876575-rs9464793-rs4712253) were significantly
different between SZ patients and HCs (c2 = 4.24, 6.37, p = 0.04 and 0.01,
respectively). In addition, in SZ patients there was a significant association in the
rs4964793 genotype for positive symptoms, and in the rs1011313 genotype for
excitement/hostility symptoms (p = 0.01 and 0.002, respectively). We found a
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significant association in the baseline symbol digital modalities test (SDMT), forward-digital
span (DS), backward-DS, and semantic fluency between SZ patients and HCs (p < 0.05
for all). Finally, the SNP rs1011313 genotypes were associated with SDMT in SZ patients
(p = 0.04).
Conclusion: This study provides further evidence that SNP rs4712253 of DTNBP1 has a
nominal association with SZ in the Han Chinese population. Such a genotype variation
may play a role in psychopathology and cognitive function.
Keywords: schizophrenia, DTNBP1, polymorphism, psychotic symptoms, cognition
INTRODUCTION
Schizophrenia (SZ) is a chronic and complex mental illness, with
up to 1% of the world's population being affected (1). Although
the etiology of SZ has not been fully elucidated, longstanding
evidence has shown that SZ is mainly a genetic disorder, with up
to 80% heritability (2, 3). SZ genetic research often focuses on
identifying linkage regions, candidate genes and single
nucleotide polymorphisms (SNPs). A genome wide association
study with a large sample size found 108 susceptibility loci
associated with SZ, underscoring the complex genetic
component of SZ (4). Some previous studies have suggested
that multiple individual mutations could alter genes in
neurotransmitter pathways such as the glutamatergic system,
which contribute to the development of SZ (5, 6).
As one of the primary excitatory neurotransmitters,
glutamate plays an important role in neuronal development,
synaptic plasticity, and neurotoxicity in the central nervous
system (7). Glutamatergic neurotransmission dysfunction
might be associated with negative symptoms and cognitive
symptoms of SZ (8, 9). The glutamatergic pathway has been
considered as a new therapeutic target, in addition to the
dopaminergic pathway, for SZ (10). The gene encoding
dystrobrevin-binding protein 1 (DTNBP1, locus: 6p24-21) was
reported as a susceptibility factor for SZ (11) and was initially
identified through multipoint linkage analysis of Irish high-
density pedigrees (12, 13). Based on results of previous studies,
some researchers believed that the neural pathway involved in
DTNBP1 may constitute a potential therapeutic target for the
treatment of SZ (10, 14), and suggested that DTNBP1 plays a role
underlying the etiology of SZ.
Further studies have supported the role of DTNBP1 as a
susceptibility gene of SZ. Li et al. found a correlation between
SNP rs2619528 and SZ in 638 nuclear families in the Chinese
Han families (15). Additional studies reported an association
between SNP rs3213207 and SZ in Norwegian (155 patients),
Spanish (589 patients vs 615 controls), and Chinese (638 nuclear
families) populations (8, 15, 16). SNPs rs9370822, rs1997679,
and rs4236176 were found to be associated with SZ in the
Caucasian population (160 patients vs 259 controls) (17). In
addition, a meta-analysis confirmed a strong correlation between
DTNBP1 and SZ (18). Previous studies found a protective effect
of the rs6459409 SNP and the estimated/phased CT diplotype
(rs6459409-rs9476886) in males for the development of SZ (14),
as well as a significant association between rs2005976 and
rs2691528, and between rs2005976 and rs760761 in Chinese
(638 nuclear families) and Scottish (580 patients vs 620 controls)
populations, respectively (15). However, some inconsistent
results have been reported. For example, rs3213207 was found
not to be a susceptibility site in UK and Korean populations (19,
20). Some studies reported that the SNPs rs742106, rs3829893,
rs4712253, rs9476886, rs1011313, and rs2619539 were not
susceptibility sites in different populations (15–17, 19–21);
these findings were confirmed in a meta-analysis (18).
To further clarify the role of DTNBP1 in SZ, we carried out a
case-control study to investigate potential associations among
DTNBP1 SNPs, and to explore the correlation between genotype
and psychopathology and cognition in the Han Chinese population.
MATERIALS AND METHODS
Subjects
Regulations governing this research were based on the principles
of the World Medical Association Declaration of Helsinki and the
Ethics Committee of the Second Affiliated Hospital of Xinxiang
Medical University (Xinxiang, China). All participants involved in
this study signed an informed consent form.
Participants were recruited from the Second Affiliated
Hospital of Xinxiang Medical University. We included a total
of 1,559 patients with SZ (stage 1 vs 2 = 528 vs 1,031) and 1,149
healthy controls (HCs, stage 1 vs 2 = 528 vs 621). All patients
were born and lived in the northern part of Henan Province,
China. All of their biological grandparents and parents were of
Chinese Han origin. HCs were from the same geographic areas;
the inclusion and exclusion criteria of HCs were the same as
reported in our previous studies (5, 22).
The diagnostic criteria for SZ were based on the Diagnostic
and Statistical Manual of Mental Disorders-Fourth Edition. The
psychopathology of SZ was assessed using the Positive and
Negative Syndrome Scale (PANSS) (23) that includes five
factors (24). Evaluation of antipsychotic efficacy after 6 weeks
of treatment of SZ patients were assessed to determine the
reduction in the PANSS score; the responder group exhibited a
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>50% reduction and the non-responder group exhibited a ≤50%
reduction (25). Cognitive function in SZ patients was assessed
using the symbol digital modalities test (SDMT), and also with
forward-digital span (DS), backward-DS, and semantic fluency.
Genotyping
Peripheral blood samples were collected from all subjects using
evacuated tubes containing EDTA anticoagulant. Genomic DNA
was extracted from white blood cells using the RelaxGene Blood
DNA System (Tiangen Biotech, Beijing, China). Genotyping was
performed using Illumina GoldenGate assays on a BeadStation
500G Genotyping System (Illumina, San Diego, CA, USA) in
stage 1 per our previous studies (5, 22, 26). The llumina 660K
Genotyping System was using to genotyping in stage 2.
Statistical Analyses
Statistical analyses were described in detail elsewhere (5, 22, 26).
The Hardy–Weinberg equilibrium (HWE), one of most
important principles of population genetics, was used to
evaluate the genetic composition and differences in the study
populations. Specifically, inbreeding, population stratification,
and selection can be induced by the deviations of the HWE (27,
28). Minor allele frequency (MAF) is the frequency of the second
most common allele in a given population, and the MAF
thresholds strongly affect population structure (29). G*Power
software was used to calculate power (http://www.gpower.hhu.
de/). The online software SNPStats (30) was used to analysis
sex/genotype interactions (https://www.snpstats.net/preproc.
php). Haploview V4.1 was used to assess genotypes, and allele
and haplotype frequency (31). Associations analyses between
different genotypes and five factors of PANSS were performed
using one-way analysis of variance (ANOVA) with age, age at
illness onset and illness duration as covariables (SPSS version
25.0, IBM Inc., Armonk, NY, USA). P < 0.05 was considered
statistically significant. Bonferroni corrections were used for
multiple comparisons.
RESULTS
Demographic Characteristics and Clinical
Information
To identify allelic variants of the DTNBP1 gene that were
associated with SZ in the Chinese Han population, allele and
genotype frequencies of 14 SNPs in stage 1, and ten SNPs in
stage 2, were analyzed. As shown in Table 1, a total of 1,559 SZ
patients (stage 1 vs 2 = 528:1,031) and 1149 (stage 1 vs 2 =
528:621) HCs were recruited in this study. There were no
significant differences in the two groups in respect to either age
and gender in stage 1 (p = 0.95 and 1.00, respectively) or in
respect to gender in stages 1 and 2 combined (p = 0.21).
However, there was a significant difference between the two
groups in respect to age for combined samples (p < 0.01).
Significant differences between the two groups were also found
in respect to family history in stage 1 and in the combined
samples (p <0.01 for both). For a power above 80%, the effect
size is 0.2, and 310 SZ patients and 310 HCs are needed. In
stage 1, power analyses revealed that the total sample size (n =
1,056, SZ patients vs HCs = 528:528) had a power of 0.94 to
detect a small effect (r = 0.2) for genotype frequency. The
sample size (n = 2,112) had a power of 0.99 to detect a small
effect (r = 0.2) for allele frequency. Therefore, there was also
strong statistical power in stage 2 (n =1,652, SZ vs HCs
= 1,031:621).
Genotype Analysis
The genotype distribution of the SNPs did not significantly
deviate from the HWE except for SNP rs1011313 in stage 1 SZ
patients, and rs9464793 in stage 2 SZ patients. In stage 1, we
found a statistically significant association in respect to allele
frequency and genotype for SNP rs742106 between SZ patients
and HCs (p = 0.02 and 0.008, respectively; Table 2). The
associations disappeared after Bonferroni's correction (p > 0.05
for both). After breaking down the cohort by gender, the above
TABLE 1 | Demographic characteristics of the schizophrenia and healthy controls.
Variables S1 S1&S2
SZ HCs P value SZ HCs P value
N 528 528 1559 1149
Age (years) 27.32 ± 8.03 27.73 ± 8.01 0.95 21.27 ± 14.57 23.56 ± 18.81 <0.01
Age of Oneset (years) 23.47 ± 8.26 NA 16.09 ± 12.06 NA
Duration of Illness (years) 6.18 ± 5.91 NA 7.69 ± 7.46 NA
Gender (male/female) 1.00 0.21
Male 264 264 801 552
Female 264 264 758 597
Family history <0.01 <0.01
Yes 82 0 264 0
No 446 528 1,295 1,149
Diagnosis Subtype
Paranoid 528 NA 1,335 NA
Undifferentiated 0 NA 197 NA
Catatonic 0 15
Residual 0 12
S1, Stage 1; S2, Stage 2; SZ, Schizophrenia, HC, health controls.
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associations were only found in males (c2 = 12.11, p = 0.002). We
also found significant gender/genotype interaction at SNP
rs742106 (p = 0.029). However, there were no significant
associations in respect to allele frequency and genotype at the
other 13 SNPs (rs16876575, rs9464793, rs4712253, rs9370823,
rs9358063, rs3829893, rs1011313, rs2619533, rs4715986,
rs12199640, rs2619539, rs2619542, and rs9476886) between SZ
patients and HCs (p > 0.1 for all).
We were not able to find significant associations between SZ
and HCs at SNP rs742106 in stage 2 (p = 0.72 and 0.61,
respectively; Table 3). In addition, there were no significant
associations in respect to allele frequency and genotype at the
other nine SNPs (rs16876575, rs9464793, rs4712253, rs9370823,
rs9358063, rs3829893, rs1011313, rs1047631, and rs1997679)
between SZ and HCs in the stage 2 (p > 0.1 for all).
Furthermore, no significant association for gender between SZ
and HCs in stage 2 was found (p > 0.05).
After combining stages 1 and 2, there were no significant
associations for allele and genotype at SNP rs742106 (p = 0.40
and 0.18; respectively). However, there was significant association in
respect to allele frequency at SNP rs4712253 between SZ patients
and HCs in stages 1 and 2 combined (p = 0.03). Meanwhile, there
was a trend association in respect to genotype at SNP rs4712253
between two groups in stages 1 and 2 combined (p = 0.05). The
association disappeared after employing Bonferroni's correction
(p > 0.05). After breaking down the cohort by gender, there was a
significant association in respect to genotype at SNPs rs4712253 and
rs9370823 for males, and SNP rs2619539 for females between SZ
patients and HCs in stages 1 and 2 combined (c2 = 11.10, 8.10, and
8.49; p =0.004, 0.017, and 0.014, respectively; data not shown). We
also found significant gender/genotype interaction at SNP
rs4712253, rs9370823, and rs2619539 in stages 1 and 2 combined
(p = 0.024, 0.048, and 0.041, respectively). After breaking down the
cohort by family history of SZ, there was a significant difference at
SNP rs9464793 in stages 1 and 2 combined (c2 = 8.04, p = 0.018,
data not shown).
Haplotype Analysis
For more in-depth analysis of the haplotype structure of stages 1
and 2 combined, standardized D′ and r2 values were used to
evaluate the pairwise LD of 16 SNPs in SZ patients and HCs.
Haplotypes were formed by 16 SNPs of DTNBP1. The locations
of these SNPs inDTNBP1, the LD structure, and the D′ values for
all variants are shown in Figure 1. Sixteen SNPs formed three LD
blocks and 12 haplotypes; only haplotype GAG and GAA
(rs16876575-rs9464793-rs4712253) significantly differed
between SZ patients and HCs (p = 0.04 and 0.01, respectively,
Supplementary Table 1).
Genotype Variation and Psychopathology
Analysis
To explore the associations between SNP genotype variations
and psychopathology, we selected 672 SZ patients (sample 1 vs
2 = 228 vs 444) who had PANSS scores. Among the five PANSS
factors, we found that positive symptom scores were significantly
different at rs9464793 between the GG and AA s in stages 1 and 2
combined (p = 0.013). Meanwhile, the excitement/hostility factor
scores were significantly different among the three genotypes of
rs1011313 in stages 1 and 2 combined (p = 0.002, Table 4). No
significant differences between SNP genotype variations and
psychopathology were found at the other 14 SNPs (rs742106,
rs16876575, rs4712253, rs9370823, rs9358063, rs3829893,
rs2619533, rs4715986, rs12199640, rs2619539, rs2619542,
TABLE 2 | Genotype and allele frequencies of 14 SNPs in the DTNBP1 gene in SZ patients and HCs.
SNP# dbSNP ID Allele
(D/d)a
SZ HCs p-value
nb HWE(p) Genotype MAF nb HWE(p) Genotype MAF
DD Dd dd DD Dd dd Genotype Allele
1 rs742106 A/G 528 0.73 153 266 109 0.46 528 0.60 192 248 88 0.40 0.02(0.56)* 0.01(0.22)*
2 rs16876575 G/A 527 0.53 373 143 11 0.16 528 0.35 362 154 12 0.17 0.73 0.45
3 rs9464793 A/G 527 0.52 449 76 2 0.08 528 0.09 444 77 7 0.09 0.24 0.39
4 rs4712253 G/A 527 0.34 175 267 86 0.42 528 0.87 201 251 76 0.38 0.34 0.11
5 rs9370823 G/A 528 0.22 130 278 120 0.49 528 0.52 149 256 123 0.47 0.32 0.48
6 rs9358063 G/A 527 0.14 405 118 4 0.12 525 0.29 395 120 13 0.14 0.09 0.20
7 rs3829893 G/A 528 0.92 325 179 24 0.21 527 0.81 330 176 22 0.21 0.93 0.71
8 rs1011313 G/A 527 0.00 306 185 36 0.24 528 0.80 320 187 21 0.22 0.15 0.12
9 rs2619533 A/T 526 0.03 449 70 7 0.08 528 0.09 444 77 7 0.09 0.83 0.60
10 rs4715986 T/A 524 0.57 255 225 44 0.30 527 0.73 260 218 49 0.30 0.81 0.95
11 rs12199640 G/A 528 0.36 357 158 13 0.17 528 0.63 374 139 15 0.16 0.41 0.38
12 rs2619539 C/G 527 0.43 256 228 43 0.30 528 0.83 261 219 48 0.30 0.78 0.98
13 rs2619542 A/G 528 0.30 255 231 42 0.30 527 0.84 260 219 48 0.30 0.68 0.98
14 rs9476886 G/A 528 0.13 238 244 46 0.32 528 0.84 233 237 58 0.33 0.46 0.43
SZ, Schizophrenia; HCs, health controls.
aMajor/minor allele, major and minor alleles are denoted by D and d, respectively.
bNumber of samples with well genotype.
*p value of Bonferroni correction.
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rs9476886, rs1047631, and rs1997679) in stages 1 and 2
combined (p > 0.4 for all, data not shown).
Genotypes and Medication
Efficacy Analysis
We further explored the association between medication efficacy
and genotypes. The PANSS scores of 504 SZ patients were tested
before and after 6 weeks of antipsychotic medication treatment.
The medication efficacy of SZ patients was 374 response and 130
non-response. No association was found between efficacy and
genotypes at the 16 SNPs (p >0.05 for all, data not shown).
Genotypes and Cognitive
Function Analysis
In stage 2, we selected 142 SZ patients and 191 HCs who had
finished cognitive function tests, including SDMT, forward-DS,
backward-DS, and semantic fluency. We found significant
association in the baseline SDMT, forward-DS, backward-DS
and semantic fluency between SZ patients and HCs (p <0.05 for
all, Supplementary Table 2). Further, we found association in
SDMT and forward-DS between the 6-week and baseline
treatments (p = 0.002 and 0.0001, respectively). Meanwhile,
only SNP rs1011313 genotype had association with the
baseline forward-DS (F = 3.41, p = 0.036; data not shown).
DISCUSSION
This study aimed to explore the association of DTNBP1
polymorphisms in patients with SZ and psychopathology and
cognition in the Han Chinese population during two stages. We
found significant differences in allele frequencies at SNP
rs4712253 between SZ patients and HCs. We also found that
the rs1011313 genotypes could be associated with excitement/
hostility and cognition symptoms in SZ patients.
The present study revealed nominal associations in regard to
genotypes and allele frequencies between paranoid SZ patients and
HCs at rs742106 in stage 1, and those differences only occurred in
male with paranoid SZ. To replicate this finding in other subtypes,
we selected an independent sample in stage 2. However, there were
no significant associations at rs742106 in stage 2 and stages 1 and 2
combined. These results were consistent with a previous study in
Caucasian populations (17). Further, we found a nominal
association related to allele frequency between SZ patients and
HCs at rs4712253, but previous studies in Caucasian populations
showed conflicting results (17). These inconsistent results may be
due to population heterogeneity (Caucasian vs Chinese population).
Also, we found no significant association in relation to genotypes or
allele frequency between SZ patients and HCs at rs1011313 and
rs2619539; these results were consistent with previous studies and a
TABLE 3 | Genotype and allele frequencies of 10 SNPs in the DTNBP1 gene in SZ patients and HCs.
SNP# dbSNP ID Allele
(D/d)a
Stage SZ HCs p-value
nb HWE(p) Genotype MAF nb HWE(p) Genotype MAF
DD Dd dd DD Dd dd Genotype Allele
1 rs742106 A/G 1 528 0.73 153 266 109 0.46 528 0.60 192 248 88 0.40 0.02 (0.56)* 0.01(0.22)*
2 1,061 0.69 335 528 198 0.43 621 0.28 185 320 116 0.44 0.72 0.61
1&2 1,589 0.62 488 794 307 0.44 1,149 0.69 377 568 204 0.42 0.40 0.18
2 rs16876575 G/A 1 527 0.53 373 143 11 0.16 528 0.35 362 154 12 0.17 0.73 0.45
2 340 0.98 238 93 9 0.16 621 0.28 449 162 10 0.15 0.47 0.33
1&2 867 0.62 611 236 20 0.16 1,149 0.17 811 316 22 0.16 0.83 0.83
3 rs9464793 A/G 1 527 0.52 449 76 2 0.08 528 0.09 444 77 7 0.09 0.24 0.39
2 341 0.00 192 106 43 0.28 621 0.00 388 158 75 0.25 0.14 0.11
1&2 868 0.00 641 182 45 0.16 1,149 0.00 832 235 82 0.17 0.62 0.15
4 rs4712253 G/A 1 527 0.34 175 267 86 0.42 528 0.87 201 251 76 0.38 0.34 0.11
2 1,061 0.20 348 537 176 0.42 621 0.79 228 294 99 0.40 0.26 0.19
1&2 1,588 0.11 523 804 262 0.42 1,149 0.93 429 545 175 0.39 0.05 (0.80)* 0.03 (0.48)*
5 rs9370823 G/A 1 528 0.22 130 278 120 0.49 528 0.52 149 256 123 0.47 0.32 0.48
2 1,062 0.81 264 527 271 0.50 618 0.89 168 310 140 0.48 0.34 0.15
1&2 1,590 0.62 394 805 391 0.50 1,146 0.73 317 566 263 0.47 0.21 0.10
6 rs9358063 G/A 1 527 0.14 405 118 4 0.12 525 0.29 395 120 13 0.14 0.09 0.20
2 339 0.21 255 81 3 0.13 618 0.59 482 126 10 0.12 0.31 0.51
1&2 866 0.06 660 199 7 0.12 1,143 0.24 877 246 23 0.13 0.07 0.67
7 rs3829893 G/A 1 528 0.92 325 179 24 0.21 527 0.81 330 176 22 0.21 0.93 0.71
2 1,061 0.84 648 363 49 0.22 621 0.60 403 197 21 0.19 0.30 0.08
1&2 1,589 0.82 973 542 73 0.22 1,148 0.60 733 373 43 0.20 0.37 0.13
8 rs1011313 G/A 1 527 0.00 306 185 36 0.24 528 0.80 320 187 21 0.22 0.15 0.12
2 1,060 0.68 613 383 64 0.24 621 0.44 366 217 38 0.24 0.88 0.74
1&2 1,587 0.33 919 568 100 0.24 1,149 0.96 686 404 59 0.23 0.37 0.20
9 rs1047631 A/G 2 1,062 0.52 1,021 41 0 0.02 621 0.64 598 23 0 0.02 0.87 0.87
10 rs1997679 G/A 2 1,061 0.58 890 165 6 0.08 620 0.92 516 99 5 0.09 0.81 0.65
SZ, Schizophrenia; HCs, Health controls; MAF, Minor allele frequency; HWE, Hardy–Weinberg equilibrium; SNP, Single nucleotide polymorphism.
aMajor/minor allele, major and minor alleles are denoted by D and d, respectively.
bNumber of samples with well genotype.
*p value of Bonferroni correction.
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meta-analysis that included Chinese populations (15, 16, 18–21, 32).
Further, although we found significant gender/genotype interaction
at SNP rs9370823, and rs2619539 in stages 1 and 2 combined.
However, the P-value of our results were near 0.05, and these results
may be easily reflected type I error. Therefore, further study needs to
enlarge the sample size to verify these findings.
Recent meta-analysis revealed that there was no significant
association between rs1047631 and SZ in six studies, which in
total included 2,764 SZ patients and 3,253 HCs in the European
population (33). Our results were consistent with this finding in
regard to the Han Chinese population. Meanwhile, previous studies
reported that the G allele of rs1047631 may be a risk factor for SZ in
the European population (34, 35). However, our results concluded
that no association was present in the Han Chinese population.
Furthermore, we found no significant association of rs1997679 in
SZ patients, this was inconsistent with a previous study (17).
However, our results were consistent with a previous study that
reported no association of rs9370823, rs3829893, rs1047631, and
rs9476886 with SZ (17). Moreover, we found that seven SNPs
(rs16876575, rs9464793, rs9358063, rs2619533, rs4715986,
rs12199640, and rs2619542) were not associated with SZ that
were not reported in the previous study.
There is conflicting available data on the SNPs rs4712253 and
rs1047631. These differences may be due to unknown population
stratification (15, 17), limited sample size (17), and/or sample
heterogeneity (19). To control for these factors, subjects recruited
in our study were living in the NorthHenan provinces and belonged
to the same population group based on structure analyses.
TABLE 4 | Association analyses between SNPs and five factors of PANSS in SZ patients.
SNP Genotype N Total PANSS Positive Negative Depression/anxiety Cognition Excitement/hostility
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
rs9464793 AA 487 87.94 19.32 14.29 3.61 23.69 7.68 10.34 5.37 17.51 5.92 15.26 5.52
AG 70 88.51 19.27 14.87 3.87 23.56 7.91 9.89 6.22 17.69 5.80 15.59 6.48
GG 4 92.50 6.35 19.25a 2.754 30.25 1.50 7.75 5.19 19.25 6.40 14.50 4.20
rs1011313 GG 383 87.22 18.61 14.36 3.76 23.65 7.63 9.80 5.14 17.31 5.96 15.38 5.76
AG 236 89.47 15.53 14.64 3.25 23.48 6.82 9.67 5.36 18.18 5.29 16.81b 5.35
AA 53 87.77 25.48 13.74 4.23 24.42 8.60 10.51 6.02 18.25 7.00 14.38 5.85
ap = 0.013, compared with AA genotype.
bp = 0.002, compared with each genotype; LSD tests, Bonferroni.
FIGURE 1 | Haplotype block structure of the DTNBP1 gene in both SZ patients and HCs in stage 1 and 2 samplese combined. The index association SNP is
represented by a diamond. The colors of the remaining SNPs (circles) indicate LD with the index SNP based on pairwise r2 values from our data.
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Moreover, we potentially improved the power to detect disease
associations by only selecting paranoid SZ patients in stage 1 and by
enlarging the sample size in stage 2. Therefore, we believe our results
to be more reliable and consistent than previous studies.
In previous studies,DTNBP1 haplotypes were found to be risk
factors for SZ and protective for male CT-haplotype carriers (14,
15, 36). The study revealed a significant association with SZ with
the haplotypes TA and CC, which had an eminent protective
effect toward SZ (32). In our study, the haplotypes GAG and
GAA inDTNBP1 were significantly associated with SZ. Although
the results were not in line with previous studies, they supported
the fact that the haplotypes may be risk factors for SZ.
SZ is characterized by several symptom domains: positive
symptoms, negative symptoms, disorganization of thoughts and
behaviors, and cognitive deficits (37). Several studies have explored
the association between DTNBP1 and positive symptoms (38),
negative symptoms (8), depression symptoms, anxiety symptoms
(39), and cognitive deficits (9). In previous studies, analyses of
DTNBP1 tag SNP (e.g., rs1011313) and haplotypes found no
conclusive evidence of any association with anxiety or depression
disorders (39). Our results were not only consistent with this study,
but we also found genotypes of rs1011313 to be associated with
excitement and hostility symptoms. A previous study revealed that
rs1997679, rs42361617, and rs9370822 were associated with
hallucinations, including visual, auditory, and olfactory (38).
Therefore, our founding that genotypes of rs9464793 are
associated with positive symptoms are also supported.
Cognitive deficits are a core feature of SZ. Meanwhile, a meta-
analysis suggested that SZ patients who were minor allele carriers of
rs1018381 and rs2619522 had lower cognitive ability scores (9).
Similar to a previous study (40), we found that cognitive deficits in
SZ patients were associated with genotypes of rs1011313.
This study had several limitations. Our sample size was not
large enough to test for cognitive functions. The samples were
collected at different times, which meant that the measurement
of cognitive function in some samples was not finished.
Therefore, further studies are needed with a larger cohort to
explore the association between gene variation and cognitive
function in SZ. Meanwhile, the statistical power in the current
data could be low. Therefore, the improvement of statistical
power could better explore the common variation of
schizophrenia and further study needs to enlarge the sample
size to increase statistical power.
CONCLUSION
In summary, this study provides further evidence that SNP
rs4712253 of DTNBP1 has a nominal association with SZ in
the Han Chinese population. This genotype variation may play
an important role in psychopathology and cognitive function in
SZ. Taken together, the results indicate that genetic variations of
DTNBP1 may be associated with SZ and influence
psychiatric symptoms.
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